Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721964 | 0.86 | MAOB (0.65) | MAOAMAOBNPC1MAPTRAB9A | |
| SCHEMBL31668679 | 0.84 | MAOA (0.67) | ESR1MAOAMAOBNPC1MAPT | |
| SCHEMBL28914186 | 0.83 | ESR1 (0.52) | ESR1MAOATYRHTR6PYGL | |
| SCHEMBL4518903 | 0.83 | MAOA (0.52) | ESR1MAOAMAOBTYRNPC1 | |
| SCHEMBL29978546 | 0.83 | ESR1 (0.60) | ESR1MAOATYRNPC1MAPT | |
| SCHEMBL5490235 | 0.83 | ESR1 (0.60) | ESR1MAOATYRNPC1MAPT | |
| SCHEMBL22803724 | 0.79 | ESR1 (0.63) | ESR1MAOATYRNPC1MAPT | |
| SCHEMBL4892478 | 0.77 | ESR1 (0.61) | ESR1MAOATYRNPC1MAPT | |
| SCHEMBL31668714 | 0.77 | ESR1 (0.61) | ESR1MAOAMAOBNPC1MAPT | |
| Hydrochloric Acid SCHEMBL30940022 | 0.76 | ESR1 (0.60) | ESR1MAOATYRNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107629022-B | Antibacterial synergist and preparation method and application thereof | 上海医药工业研究院 | 2024-11-12 | — | — | CN | disclosed |
| EP-4103278-A1 | SMALL MOLECULE STING ANTAGONISTS | Curadev Pharma Pvt. Ltd. (IN) | 2022-12-21 | — | — | EP | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7723374-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723374-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| US-7491831-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7476746-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476746-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| US-7348338-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348338-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | ESR1 1794/4885MAOA 2917/4885MAOB 2635/4885 |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | ESR1 307/4885MAOA 3993/4885MAOB 3980/4885 |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | ESR1 307/4885MAOA 3993/4885MAOB 3980/4885 |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | ESR1 307/4885MAOA 3993/4885MAOB 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.